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Objectives The aim of this study was to examine whether kidney dysfunction is associated with the type of clinical presen-
tation of coronary heart disease (CHD).
Background Reduced kidney function increases the risk for developing CHD, but it is not known whether it also influences the
acuity of clinical presentation, which has important prognostic implications.
Methods A case-control study was conducted of subjects whose first clinical presentation of CHD was either acute myo-
cardial infarction or stable exertional angina between October 2001 and December 2003. Estimated glomerular
filtration rate (eGFR) before the incident event was calculated using calibrated serum creatinine and the abbrevi-
ated MDRD (Modification of Diet in Renal Disease) equation. Patient characteristics and use of medications
were ascertained from self-report and health plan databases. Multivariable logistic regression was used to exam-
ine the association of reduced eGFR and CHD presentation.
Results A total of 803 adults with incident acute myocardial infarctions and 419 adults with incident stable exertional
angina who had baseline eGFRs 130 ml/min/1.73 m2 were studied. Mean eGFR was lower in subjects
with acute myocardial infarctions compared with those with stable angina. Compared with eGFR of 90 to
130 ml/min/1.73 m2, a strong, graded, independent association was found between reduced eGFR and pre-
senting with acute myocardial infarction, with adjusted odds ratios of 1.36 (95% confidence interval: 0.99 to
1.86) for eGFR 60 to 89 ml/min/1.73 m2, 1.55 (95% confidence interval: 0.92 to 2.62) for eGFR 45 to 59
ml/min/1.73 m2, and 3.82 (95% confidence interval: 1.55 to 9.46) for eGFR 45 ml/min/1.73 m2 (p  0.001
for trend).
Conclusions An eGFR 45 ml/min/1.73 m2 is a strong, independent predictor of presenting with acute myocardial infarction
versus stable angina as the initial manifestation of CHD. (J Am Coll Cardiol 2011;58:1600–7) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.07.010Cardiovascular disease causes more than 50% of deaths in
patients with chronic kidney disease (CKD) and end-stage
renal disease (ESRD) (1,2). CKD is an independent risk
factor for both de novo and recurrent cardiovascular disease
(3–5). There is a graded independent association between
reduced estimated glomerular filtration rate (eGFR) and the
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Patients with CKD have a higher risk for dying of cardio-
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October 4, 2011:1600–7 Kidney Disease and Clinical Presentation of CHDelements, lipids, and debris. The development of these plaques
is often manifested by stable angina symptoms. When the
plaque ruptures, prothrombotic material in the center of the
plaque is exposed to the blood. Myocardial infarction occurs
when the ruptured plaque progresses to thrombosis, resulting
in complete occlusion of the affected coronary artery with
subsequent infarction of the downstream myocardial tissue.
The constellation of symptoms associated with this sequence of
events is an important identifier of CHD.
Patients with ESRD often have atypical presentations of
CHD. Silent CHD (lack of angina symptoms) is common
in patients with ESRD (8,9). One study found that 44% of
a large cohort of asymptomatic hemodialysis patients had
significant CHD (10). Although there may be an associa-
tion between silent CHD and ESRD, the clinical presen-
tation of CHD in the much larger population of patients
with CKD has not been well defined.
CKD is frequently associated with hypertension, dyslipide-
mia, and diabetes, all of which are major risk factors for
endothelial dysfunction and atherosclerosis. Additionally,
unique pathophysiologic mechanisms associated with CKD,
such as anemia, hyperphosphatemia, and inflammation, may
play important roles in the initiation of cardiovascular disease.
The synergistic effect of these processes may accelerate coro-
nary atherosclerosis in patients with CKD and potentially
affect the type of clinical presentation of CHD by altering the
stability of coronary plaques and vascular function.
Although it is well accepted that the CKD population has
an increased burden of cardiovascular disease, it is not known
if the high mortality from cardiovascular disease is due primar-
ily to the high incidence of cardiovascular disease events or
because patients with CKD experience more severe types of
events. To address this question, we examined whether CKD
influenced the initial clinical presentation and clinical stability
of CHD in a large community-based sample. We compared
patients whose first presentation of CHD was acute myocardial
infarction with patients with incident stable angina, because
these symptoms are clinically and physiologically distinct on
the spectrum of coronary atherosclerosis. We hypothesized
that patients presenting with acute myocardial infarction are
more likely to have CKD than those presenting with stable
angina and that the association is related to the severity of
pre-existing CKD.
Methods
Study sample. The source population included adults (age
20 years) who received medical care within Kaiser Per-
manente of Northern California, a large, integrated health
care delivery system providing comprehensive care to more
than 3 million members in the San Francisco and greater
Bay area. Previous studies have shown that the membership
is representative of the local surrounding and statewide
insured adult population, apart from slightly lower propor-
tions of persons at the extremes of age and income level
(11). The ADVANCE (Atherosclerotic Disease, Vascular cFunction, and Genetic Epidemi-
ology) study enrolled patients
with either acute myocardial in-
farction or stable exertional an-
gina as their first presentation of
clinical CHD (12). The institu-
tional review boards of the col-
laborating institutions approved
the study, and informed consent
was obtained in all participants.
We conducted a case-control
study to examine the influence of
reduced kidney function on the
likelihood of presenting with ei-
ther acute myocardial infarction
or stable exertional angina as the
first clinical expression of CHD.
Incident acute myocardial infarction cases. Recruitment
of study subjects has been described in detail previously (12).
riefly, we identified men age 45 to 75 years and women age
5 to 75 years who had acute myocardial infarction as their
rst presentation of clinical CHD between October 28,
001, and December 31, 2003, by weekly searches of
utomated laboratory for elevated cardiac enzymes and
ospital discharge databases for primary discharge diagnosis
f myocardial infarction (International Classification of
isease-Ninth Revision-Clinical Modification code 410).
e excluded subjects who had evidence in automated
ospital discharge, ambulatory visit, pharmacy, and labora-
ory databases of previous diagnosed CHD, prior hospital-
zations complicated by elevated serum troponin I levels,
eceiving chronic dialysis, prior organ or bone marrow
ransplantation, lack of a primary care provider, death before
tudy contact, serious cognitive impairment or uncontrolled
sychiatric conditions, or receiving prescriptions for nitro-
lycerin more than 14 days before the index date. We also
xcluded patients who did not have serum creatinine mea-
urements available before myocardial infarction. Subjects
ere screened by telephone interview to confirm the absence
f prior diagnosed CHD, coronary revascularization, or
schemic symptoms more than 14 days before admission for
cute myocardial infarction as well as any exclusion criteria
ot identified by health plan databases.
ncident stable exertional angina cases. We identified
en and women age 18 to 75 years who had stable
xertional angina as their first presentation of clinical CHD
etween October 28, 2001, and December 31, 2003, by
eekly searches of automated ambulatory visit databases for
ew outpatient diagnoses of angina pectoris (International
lassification of Disease-Ninth Revision-Clinical Modifi-
ation code 413.x). We applied the same exclusion criteria
s for cases of myocardial infarction described previously,
xcept that we excluded patients who received prescriptions
or nitroglycerin more than 6 months before index date.
ubjects were similarly screened by telephone interview to
Abbreviations
and Acronyms
CHD  coronary heart
disease
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
ESRD  end-stage renal
disease
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
MDRD  Modification of
Diet in Renal Diseaseonfirm the absence of prior CHD and coronary revascu-
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Kidney Disease and Clinical Presentation of CHD October 4, 2011:1600–7larization as well as any exclusion criteria not identified by
health plan databases. In addition, subjects had to report
evidence of stable chest pain or chest pressure reproduced by
the same level of physical exertion, lasting 1 min and 15
inutes, and responding to rest or nitroglycerin. Subjects
Baseline Characteristics of Adults With Acute Mor Stable Exertional Angina as the First Pres ntTable 1 B seline Char cteristics of d lts Wor Stable Exertional Angina as the
Characteristic
Prior eGFR (ml/min/1.73 m2)
Mean  SD
Median (interquartile range)
Category of prior eGFR (ml/min/1.73 m2)
90–130
60–89
45–59
45
Age (yrs)
Women
Race/ethnicity
White European/Middle Eastern
African American
Hispanic/Latino
South Asian
Asian/Pacific Islander
Native American
Non-Hispanic admixed
Annual household income
$25,000
$25,000–$49,999
$50,000–$99,999
$100,000
Refused to answer
Marital status
Married/domestic partner
Divorced/separated
Widowed
Never married
Cigarette smoking
Current
Former
Never
Alcohol use in prior 12 months
Leisure-time activity in past 12 months
Minimal
Light
Moderate
Heavy
Medical history
Stroke/transient ischemic attack
Peripheral artery disease
Diabetes mellitus
Diagnosed hypertension
Parental history of coronary heart disease
Sibling history of coronary heart diseaseould only have had symptoms lasting 6 months or less vefore the outpatient angina diagnosis and could not have
eported these symptoms to a health care provider before
heir index dates.
easurement of kidney function. Kidney function was
ssessed using eGFR calculated using the 4-variable abbre-
rdial Infarctionof CHDAcute Myocardial Infarction
Presentation of CHD
Acute Myocardial
Infarction
(n  803)
Stable Exertional
Angina
(n  419) p Value
78.2 18.7 81.2 17.9 0.006
78.0 (66.0–90.0) 80.0 (70.0–92.0) 0.006
0.07
26.5% 31.7%
59.5% 57.0%
9.8% 9.3%
4.1% 1.9%
62.5 8.4 62.1 8.4 0.35
23.8% 33.7% 0.001
0.68
67.8% 69.5%
4.6% 3.3%
9.6% 11.0%
2.1% 1.2%
5.4% 5.0%
0.0% 0.0%
10.6% 10.0%
0.28
13.2% 11.5%
25.0% 25.1%
39.3% 35.4%
15.6% 19.6%
7.0% 8.4%
0.46
72.6% 76.4%
14.3% 12.5%
8.2% 6.3%
5.0% 4.8%
0.01
9.7% 6.7%
55.5% 50.6%
34.8% 42.7%
67.7% 73.3% 0.04
0.001
34.0% 30.0%
20.8% 12.7%
32.5% 39.8%
12.8% 17.5%
10.0% 11.2% 0.51
10.5% 8.8% 0.35
29.0% 24.6% 0.10
83.4% 76.1% 0.002
46.8% 57.5% 0.001
21.2% 27.2% 0.02
Continued on next pageyocaationith
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October 4, 2011:1600–7 Kidney Disease and Clinical Presentation of CHDstudy equation (eGFR [ml/min/1.73 m2]  186  [serum
creatinine in mg/dl]1.154  [age]0.203  0.742 [if female] 
.212 [if black]) on the basis of the outpatient serum
reatinine test result found in health plan laboratory data-
ases closest to but before the index date (13). As previously
escribed, serum creatinine values were calibrated to the
ContinuedTable 1 Continued
Characteristic
Medication use within 160 days before event
Statins
Niacin
Cholestyramine
Colestipol
Colesevelam
Gemfibrozil
Fenofibrate
Beta-blockers
Calcium-channel blockers
Alpha-blockers
ACE inhibitors
ARBs
Diuretic agents
Hormone replacement therapy
Blood pressure at most recent outpatient visit before index
Systolic (mm Hg)
120
121–129
130–139
140–159
160–179
180
Diastolic (mm Hg)
80
81–84
85–89
90–99
100–109
110
Body mass index (kg/m2)
Category of body mass index (kg/m2)
25
25–29
30
Prior lipoprotein testing and results
Total cholesterol (mg/dl)
Tested
LDL cholesterol (mg/dl)
Tested
HDL cholesterol (mg/dl)
Tested
Triglycerides (mg/dl)
Tested
Values are mean  SD median (interquartile range), or %.
ACE  angiotensin converting enzyme; ARB  angiotensin recept
LDL  low-density lipoprotein; NA  not applicable.ore laboratory used to generate the MDRD estimating mquation (6). On the basis of prior work demonstrating an
mportant eGFR threshold of 45 ml/min/1.73 m2 for risk
or adverse outcomes (6), and the recently published up-
ated Kidney Disease: Improving Global Outcomes guide-
ines (14), we used the following classification system to
efine CKD: 90 to 130, 60 to 89, 45 to 59, and 45
Acute Myocardial
Infarction
(n  803)
Stable Exertional
Angina
(n  419) p Value
21.9% 41.3% 0.001
0.9% 0.7% 0.77
0.4% 0.7% 0.42
0.1% 0.5% 0.24
0.0% 0.0% NA
1.6% 2.6% 0.23
0.1% 0.7% 0.09
21.1% 48.4% 0.001
14.7% 10.3% 0.03
2.2% 1.2% 0.20
22.7% 27.0% 0.10
3.2% 3.8% 0.60
21.5% 24.6% 0.23
31.9% (of 191
women)
36.9% (of 141
women)
0.35
(n  714) (n  389) 0.05
16.5% 22.9%
12.8% 15.7%
27.9% 23.9%
31.4% 26.5%
9.1% 9.3%
2.4% 1.8%
(n  714) (n  390) 0.001
55.5% 67.2%
16.8% 10.5%
11.6% 7.7%
11.8% 11.3%
3.6% 1.0%
0.7% 2.3%
29.3 5.5 29.0 4.8 0.31
0.74
20.2% 19.7%
42.6% 44.8%
37.2% 35.5%
221.6 39.5 217.8 41.3 0.13
95.3% 97.6% 0.05
137.0 34.3 131.7 35.4 0.02
82.2% 91.0% 0.001
45.1 12.5 47.1 13.1 0.01
91.8% 96.4% 0.002
195.0 115.6 198.9 126.7 0.62
82.9% 91.4% 0.001
ker; CHD  coronary heart disease; HDL  high-density lipoprotein;datel/min/1.73 m2. Patients on maintenance dialysis were
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ESRD registry (6).
Covariates. Age at index date was based on self-report and
onfirmed in health plan databases. Subjects also provided
elf-reported information on gender, racial and ethnic
roup, marital status, employment status, annual household
ncome, parental and sibling history of CHD, personal
edical history of stroke, prior peripheral artery disease,
iabetes mellitus, and hypertension. Self-reported informa-
ion on smoking status at index date (current, former, or
ever) as well as alcohol drinking pattern and intensity of
eisure-time activity during the 12 months before the study
isit date were obtained. The most recent outpatient systolic
nd diastolic blood pressure values before index date were
btained from ambulatory visit databases, which have been
hown to reliably reflect chronic blood pressure levels in our
atabase (15). Body mass index (kilograms per square meter)
was measured at the study visit using standard procedures. We
used automated health plan pharmacy databases to identify
receipt of selected cardiac medications during the 160 days
before index date. This time period was chosen to identify
medications prescribed for chronic conditions, which are
generally given as a 90- to 100-day supply. We identified
recent use of 3-hydroxy-3-methylglutaryl coenzyme A re-
ductase inhibitors (statins), niacin or nicotinic acid deriva-
tives, fibrates, bile acid–binding resins, beta-adrenergic
antagonists, calcium-channel antagonists, alpha-adrenergic
antagonists, angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, diuretic agents, and, among
women, hormone replacement therapy (estrogen with or
without progestins). We searched health plan laboratory data-
bases for evidence of testing for total cholesterol, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, and triglyceride levels before index date.
LDL cholesterol values were routinely calculated using the
Friedewald equation (16). Among tested patients, we exam-
ined the most recent value for each lipoprotein component
before index date.
Statistical analysis. All analyses were performed using
SAS version 9.1 (SAS Institute Inc., Cary, North Carolina).
Differences between subjects with incident acute myocardial
infarction or stable exertional angina were compared using
Student t tests for continuous variables and chi-square tests
for categorical variables. We performed a series of multi-
variable logistic regression models to examine the associa-
tion between level of prior kidney function and the odds of
presenting with acute myocardial infarction versus stable
angina after adjustment for potential confounders. Variables
included in models were based on variables that were
significantly different between cases and controls on bivari-
ate analyses or have previously been shown to be associated
either with kidney function or acute myocardial infarction.
Variables were grouped into 4 categories: 1) sociodemographic,
family history, and life-style characteristics; 2) comorbidities;
3) blood pressure, anthropometry, and lipoprotein levels; and
4) prior cardiovascular medication use. A series of nestedmodels were conducted that additionally adjusted for each
category of covariates. For models including systolic and
diastolic blood pressure, LDL cholesterol, or HDL cholesterol
categories, patients were assigned to the “missing” category if
the data were unavailable. Model fit for the final models were
assessed using Hosmer-Lemeshow goodness-of-fit methods
(17).
Results
Distribution of kidney function and baseline characteristics.
We prospectively enrolled 930 adults with incident enzyme-
positive acute myocardial infarctions and 451 adults with
incident stable exertional angina. We excluded 127 patients
with acute myocardial infarctions and 32 patients with stable
exertional angina who had prior eGFRs130 ml/min/1.73 m2 or
o available serum creatinine data. This left a final analytic
ample of 803 patients with incident acute myocardial infarc-
ions and 419 patients with incident stable exertional angina
ho had prior eGFRs 130 ml/min/1.73 m2 (Table 1). The
edian time between the event date and the pre-event baseline
erum creatinine measurement was 157 days (interquartile
ange: 31 to 440 days). There were no significant differences in
ean age and racial or ethnic group, but there were more
omen among subjects with angina. The mean eGFR was
ower among subjects with acute myocardial infarctions com-
ared with those with stable angina, with a higher proportion
f subjects with eGFRs 45 ml/min/1.73 m2.
No significant differences were observed for annual house-
hold income or marital status between groups (Table 1).
Subjects presenting with acute myocardial infarction were
more likely to be current or former cigarette smokers and to
report minimal or light prior physical leisure-time activity
compared with those with angina, but there was no significant
difference in self-reported prior alcohol use between groups.
Subjects with acute myocardial infarctions were more likely
than those with angina to have self-reported hypertension, but
there were no other differences in prevalent noncoronary
cardiovascular disease or diabetes mellitus. Subjects with acute
myocardial infarctions were less likely than those with angina
to report parental or sibling histories of CHD.
As previously noted (12), recent statin and beta-blocker
use were higher in subjects with acute myocardial infarctions
compared with those with stable angina, but there were no
other significant differences in other medication use
(Table 1). Diastolic, but not systolic, blood pressure was
more likely to be higher among subjects with acute myo-
cardial infarction, but there were no significant differences
in the distribution of body mass index between groups.
Among tested patients, LDL cholesterol levels were on
average 5 mg/dl higher and HDL cholesterol levels 2 mg/dl
lower in subjects with acute myocardial infarctions versus
stable angina.
Level of eGFR and CHD presentation. Compared with
eGFR of 90 to 130 ml/min/1.73 m2, the unadjusted odds of
presenting with acute myocardial infarction versus stable exer-
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October 4, 2011:1600–7 Kidney Disease and Clinical Presentation of CHDtional angina were only significantly higher for eGFR 45
l/min/1.73 m2, with odds ratios of 1.25 (95% confidence
nterval: 0.96 to 1.63) for eGFR 60 to 89 ml/min/1.73 m2,
.27 (95% confidence interval: 0.81 to 1.97) for eGFR 45 to 59
l/min/1.73 m2, and 2.58 (95% confidence interval: 1.16 to
.75) for eGFR 45 ml/min/1.73 m2.
After adjustment for differences in sociodemographic,
family history, and life-style factors, we found that eGFR
45 ml/min/1.73 m2 was associated with 2.8-fold increased
odds of acute myocardial infarction versus stable exertional
angina compared with eGFR of 90 to 130 ml/min/1.73 m2
but no statistically significant increased odds for eGFR of 60
to 89 or 45 to 59 ml/min/1.73 m2 (Table 2). Further
adjustment for comorbidities, systolic blood pressure, body
mass index, and prior LDL and HDL cholesterol level did
not materially affect the adjusted odds ratios. However, after
additional adjustment for prior use of relevant cardiovascu-
lar medications, we found a stronger, graded association
between reduced eGFR and presenting with acute myocar-
dial infarction versus stable angina: compared with eGFR of
90 to 130 ml/min/1.73 m2, the adjusted odds increased
rom 1.36 for eGFR 60 to 89 ml/min/1.73 m2 to 3.82 for
eGFR 45 ml/min/1.73 m2 (p  0.001 for trend) (Table
). The Hosmer-Lemeshow goodness-of-fit test for the
nal model showed a p value of 0.10.
iscussion
he purpose of our study was to evaluate the impact of
KD on the clinical stability and the initial clinical presen-
ation of CHD (acute myocardial infarction vs. stable
xertional angina). We chose patients who presented with
table exertional angina as a control group to isolate risk
actors for clinical instability of CHD rather than underly-
ng coronary atherosclerosis. Our results suggest that the
isk for presenting with acute myocardial infarction (com-
ared with stable exertional angina) is greater in patients
ith CKD, particularly below an eGFR of 45 ml/min/1.73 m2.
he odds ratio of this association increased by nearly 3-fold
fter adjustment for sociodemographic and life-style char-
cteristics, traditional cardiovascular risk factors, and pre-
vent use of a wide range of relevant medications (Table 2).
hese results suggest that there may be alternative mecha-
Multivariate Association Between Level of Renal Function and theas Acute Myocardial Infarction Versus Stabl Exertional AnginaTable 2 Multiv riate Ass ciation Be ween Level of Re al Funcas Acute Myocardial Infarction Versus Stable Exertion
eGFR (ml/min/1.73 m2)
Ad
Model 1* Model 2†
90–130 Referent Referent
60–89 1.25 (0.96–1.63) 1.30 (0.98–1.73
45–59 1.27 (0.81–1.97) 1.38 (0.86–2.21
45 2.58 (1.16–5.75) 2.77 (1.21–6.34
*eGFR only. †Model 1 plus age, sex, race or ethnicity, family history of CHD, cigarette smoking his
and hypertension. §Model 3 plus systolic blood pressure, body mass index, and prior low-density lip
calcium-channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and d
CHD  coronary heart disease; eGFR  estimated glomerular filtration rate.isms related to CKD that promote plaque instability and
ubsequent myocardial infarction.
Coronary atherosclerosis is a spectrum of disease, ranging
rom clinically stable plaques to vulnerable plaques suscep-
ible to rupture and thrombosis. The initial expression of
HD is largely dependent on the stability of these athero-
clerotic plaques. The severity and stability of the initial
resentation of CHD significantly influences clinical man-
gement and long-term cardiovascular outcomes. Certain
opulations have unique manifestations of CHD. Our study
uggests that patients with CKD may have distinct risk
actors for plaque vulnerability.
To our knowledge, no other studies have evaluated the
mpact of CKD on the clinical stability and presentation of
HD. CKD has been a well-described risk factor for
therosclerosis and CHD, with cardiovascular disease caus-
ng the greatest mortality in the CKD population (6). A key
nderstudied question has been whether high cardiovascular
isease morbidity and mortality in this unique population is
result of both more frequent cardiovascular events (6) and
ore severe events. Our results support the hypothesis that
atients with CKD appear to have a greater likelihood of
ore clinically unstable and severe disease. Our results also
uggest that clinical efforts should be targeted to identify
his high-risk population before incident symptoms of
therosclerosis occur and that we should aim to develop
ffective interventions and strategies to shift the expression
f CHD from acute myocardial infarction to more stable
resentations in patients with CKD.
Several mechanisms can be postulated to possibly explain
he association between reduced eGFR and greater risk for
cute myocardial infarction. In addition to the high preva-
ence of “traditional” risk factors, such as hypertension,
yperlipidemia, and diabetes, patients with CKD often have
nique pathophysiologic mechanisms that may play impor-
ant roles in the initiation and acceleration of cardiovascular
isease. It is possible that these CKD-related mechanisms
ay also promote plaque vulnerability to rupture and
hrombosis. For example, it appears that atherosclerotic
laque morphology in ESRD is accompanied by marked
ubintimal calcification and medial thickening as a result of
ypertrophy and hyperplasia of vascular smooth muscle
for Presentation of CHDnd th Risk for Presentation of CHD
gina
Odds Ratio (95% Confidence Interval)
Model 3‡ Model 4§ Model 5
Referent Referent Referent
1.33 (1.00–1.78) 1.31 (0.98–1.80) 1.36 (1.00–1.86)
1.34 (0.84–2.16) 1.34 (0.82–2.19) 1.55 (0.91–2.62)
2.64 (1.15–6.10) 2.71 (1.16–6.34) 3.82 (1.55–9.46)
d physical activity level. ‡Model 2 plus prior stroke or peripheral artery disease, diabetes mellitus,
in and high-density lipoprotein cholesterol levels. Model 4 plus prior use of statins, beta-blockers,Risktion a
al An
justed
)
)
)
tory, an
oproteiuretic agents.
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Kidney Disease and Clinical Presentation of CHD October 4, 2011:1600–7cells, causing arterial stiffness, which may affect plaque
formation. Elevated pulse pressure may be a reflection of
this arterial stiffness and has been an indicator of increased
risk for cardiovascular events and mortality in patients on
hemodialysis (18,19). Also, anemia in patients with kidney
disease has been strongly associated with increased cardio-
vascular and all-cause mortality in patients with CKD and
ESRD and may increase plaque instability (20,21). Addi-
tionally, CKD-related metabolic derangements have been
associated with increased cardiovascular mortality; for ex-
ample, hyperphosphatemia may contribute to arterial calci-
fication, although the exact pathogenesis is not known
(22–25). Inflammation has also been shown to be closely
related to cardiovascular death in the CKD and ESRD
population (26,27). Models have shown that various inflam-
matory markers are elevated in CKD and may enhance the
production of free radicals that increase atherosclerosis.
Inflammation may also alter plasma protein composition
and endothelial structure to promote vascular disease (28).
The synergistic effect of these novel processes may accelerate
coronary atherosclerosis in patients with CKD and poten-
tially affect the type of clinical presentation of CHD by
altering the stability of coronary plaques and vascular
function.
Study strengths and limitations. Our study had several
strengths. Our study population was a large and diverse
sample of well-characterized community-based patients.
We were able to capture incident clinical CHD by symp-
toms and diagnostic tests such as cardiac enzymes and
electrocardiography, with careful phenotyping of the clinical
presentation of CHD. We also had calibrated outpatient
serum creatinine measurements available before the index
cardiac event.
Our study had several limitations as well. The exact
mechanism of the association between CKD and clinically
unstable CHD cannot be delineated from our study. For
example, information on circulating inflammatory or pro-
thrombotic factors was unavailable before the index event.
The timing of the last outpatient creatinine measurement
varied in the study population, and the use of a single
measurement could have led to some misclassification in
eGFR levels, even though we relied on outpatient, non–
emergency department serum creatinine measurements that
likely reflected steady-state renal function. Data on urinary
protein excretion were unavailable. We also could not
determine the pre-event use of aspirin in our study popu-
lation, because it was not available in our health plan
databases because it is routinely used as an over-the-counter
medication. Patients with acute myocardial infarctions or
stable angina who died before attempted contact were not
enrolled, which may have contributed to spectrum bias.
There may have been other residual confounders we were
unable to identify and adjust for. Although we found no
evidence of poor model fit, the Hosmer-Lemeshow
goodness-of-fit test has limited power to detect poor fit in
certain circumstances. Finally, we conducted our studyamong health plan members within a large, integrated
health care delivery system in northern California, so our
findings may not be completely generalizable to other health
care settings or to uninsured patients.
Conclusions
A reduced eGFR was associated with a greater likelihood of
presenting with acute myocardial infarction versus stable
exertional angina among patients with new-onset symptoms
of CHD. Our study suggests that patients with kidney
dysfunction are at substantially higher risk for severe,
clinically unstable CHD that are not explained by known
clinical cardiovascular risk factors and other major con-
founders. Our results support the need to focus our efforts
toward early identification of this high-risk population and
the development of effective targeted cardiopreventive in-
terventions to reduce the risk for irreversible cardiovascular
complications.
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